scholarly journals Olfactory Function in Patients with Inflammatory Bowel Disease (IBD) Is Associated with Their Body Mass Index and Polymorphism in the Odor Binding-Protein (OBPIIa) Gene

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 703
Author(s):  
Giorgia Sollai ◽  
Melania Melis ◽  
Mariano Mastinu ◽  
Danilo Paduano ◽  
Fabio Chicco ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Body Weight ◽  
Bowel Disease ◽  
Eating Habits ◽  
Olfactory Function ◽  
Olfactory Threshold ◽  
Identification Score ◽  
Healthy Control ◽  
Inflammatory Bowel ◽  
Specific Disorders

Smell strongly contributes to food choice and intake, influencing energy balance and body weight; its reduction or loss has been related to malnutrition problems. Some patients with inflammatory bowel disease (IBD), mainly Crohn’s disease (CD) and ulcerative colitis (UC), are underweight, while others are overweight. Some studies suggest that changes in eating habits could be linked to specific disorders of the olfactory functions. We assessed the olfactory performance in 199 subjects (healthy control (HC) n = 99, IBD n = 100), based on the olfactory Threshold, Discrimination and Identification score (TDI score), measured with the “Sniffin’ Sticks” test. Subjects were genotyped for the rs2590498 polymorphism of the OBPIIa gene. IBD patients showed both a slightly, but significantly, lower olfactory function and a higher BMI compared to HC subjects. Threshold (in both population) and Discrimination (in IBD patients) olfactory score were affected by the OBPIIa genotype. BMI was influenced by both health status and OBPIIa genotype. A lower olfactory function may delay the satiety sensation and thus increase meal duration and body weight in IBD patients. However, the AA genotype of the OBPIIa seems to “protect” IBD patients from more severe olfactory dysfunction.

scholarly journals Fecal Lipocalin-2 as a Sensitive and Noninvasive Biomarker in the TNBS Crohn’s Inflammatory Bowel Disease Model

2016 ◽  
Vol 44 (8) ◽  
pp. 1084-1094 ◽  
Author(s):  
Heidi Hsieh ◽  
Jeffrey Morin ◽  
Cyndi Filliettaz ◽  
Rao Varada ◽  
Shelby LaBarre ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Body Weight ◽  
Bowel Disease ◽  
Saline Water ◽  
Disease Model ◽  
Recovery Phase ◽  
Lipocalin 2 ◽  
Trinitrobenzenesulfonic Acid ◽  
Noninvasive Biomarker ◽  
Inflammatory Bowel

Colitis induced by 2,4,6-Trinitrobenzenesulfonic acid (TNBS) has been used as a model for Crohn’s disease (CD) of inflammatory bowel disease (IBD). Lipocalin-2 (Lcn-2) is an emerging and clinically relevant biomarker of IBD. We investigated the performance of serum and fecal Lcn-2 in the TNBS model of colitis. Female, 7-week-old, BALB/c mice were administered intrarectally phosphate-buffered saline/water or 30% ethanol (vehicle control groups) for 5 days or TNBS for 5 days followed by a 28-day recovery phase. Serum and fecal levels of Lcn-2 were quantified, and effects on body weight, clinical scores, colon weight and length, gross pathology, and histopathology were investigated. Increased serum Lcn-2 levels correlated only with marked to severe inflammation. A clear differentiation in Lcn-2 fecal levels between TNBS-treated and vehicle-treated control mice was most noticeable on days 2 and 3. There was a strong correlation between body weight change, histopathologic scores of inflammation, and/or fecal Lcn-2 levels on days 2 and 5. Both serum and fecal Lcn-2 levels declined over time as the colonic mucosa recovered. Fecal Lcn-2 was found to be a more sensitive biomarker (vs. serum Lcn-2) and was able to discriminate mild, moderate, and severe colonic inflammation.

HEALING THROUGH CYTOKINE REGULATION IN DNBS INDUCED INFLAMMATORY BOWEL DISEASE IN RATS BY HOLARRHENA ANTIDYSENTERICA

INDIAN DRUGS ◽  
2016 ◽  
Vol 53 (08) ◽  
pp. 57-64
Author(s):  
S. Johari ◽  
◽  
C. Joshi ◽  
T. Gandhi
Keyword(s):  
Gene Expression ◽  
Inflammatory Bowel Disease ◽  
Body Weight ◽  
Bowel Disease ◽  
Stool Consistency ◽  
Cytokine Gene ◽  
Group Iii ◽  
Group I ◽  
Holarrhena Antidysenterica ◽  
Inflammatory Bowel

The objective of the study was to ascertain antioxidant, anti-inflammatory and cytokine gene regulation activity of Holarrhena antidysenterica (HA) in dinitrobenzene sulfonic acid (DNBS) induced inflammatory bowel disease (IBD) in rats. Sprague Dawley rats were divided into 6 groups, Group I (normal), Group II (50% ethanol intracolonically on 11th day), Group III (Model). Group IV to VI were given standard drug 5-amino salicylic acid (5-ASA) (100mg/kg) and hydromethanolic extract of Holarrhena antidysenterica (MEHA) 450 mg/kg and MEHA 600 mg/kg respectively for 18 days once p.o. Colitis was induced with DNBS (180mg/kg in 50% ethanol) intracolonically in animals of Group III-VI on 11th day. Body weight, food & water intake and stool consistency of each group was noted. On 18th day, blood was collected for cortisol estimation. Colon length and weight was measured. Cytokine gene expression studies of colon in group I, II, III, IV and VI was done using Real Time RT-PCR. Colon histopathology, Disease Activity Index (DAI) and Colon Mucosal Disease index (CMDI) parameters were studied. Nitric oxide (NO), malondialdehyde (MDA), myeloperoxidase (MPO) and superoxide dismutase (SOD) were estimated in colon homogenate. DNBS model control showed significant reduction in body weight, water and food intake, SOD, colon length and significant increase in stool consistency, colon weight, MDA, MPO, NO, CMDI, DAI, cortisol, IL-4, IL-6, IL-12 and IFN-gamma cytokines gene expression. Pretreatment with 5-ASA (100mg/kg) and MEHA (450 and 600 mg/kg) significantly reversed the above. MEHA reduced severity of IBD induced by DNBS through its anti-inflammatory, antioxidant and gene modulatory activity.

scholarly journals P019 Colonic mucosal kinase activity, cytokine and chemokine profiles in inflammatory bowel disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S139-S140
Author(s):  
E Brand ◽  
B Roosenboom ◽  
B Malvar Fernandez ◽  
L Lutter ◽  
E van Koolwijk ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Kinase Activity ◽  
Cell Signalling ◽  
Explant Culture ◽  
Janus Kinase ◽  
Oncostatin M ◽  
Healthy Control ◽  
Inflammatory Bowel ◽  
The Difference

Abstract Background With the approval of tofacitinib, an oral Janus Kinase (JAK) inhibitor, modulation of kinase activity has been added to the therapeutic armamentarium of inflammatory bowel disease (IBD). Despite its established efficacy, at least a third of patients will not respond to this or other therapeutic options such as anti-tumour necrosis factor (TNF), anti-interleukin (IL)23/IL12 compounds or vedolizumab. A better understanding of the inflammatory profile could aid in tailoring drugs to individual patients. We therefore explored mucosal cytokine, chemokine and kinase activity profiles in IBD. Methods Colonic mucosal biopsies were collected from (1) patients with Crohn’s disease (CD, N = 8), (2) patients with ulcerative colitis (UC, N = 8) and (3) healthy controls (N = 4). IBD samples were collected both from inflamed and non-inflamed tissue from the same patients. All IBD patients were biological-naïve and had not used corticosteroids in the past 3 months. Biopsies were snap frozen for later kinase activity determination or directly used in a 24-h explant culture. Whole biopsy kinase activity (tyrosine, serine and threonine kinases) was assessed using the Pamgene platform. A 64-analyte panel was examined in the supernatant of the cultured biopsies employing a multiplex assay (Luminex). Results Whole-biopsy kinase activity differed between inflamed and non-inflamed mucosa of IBD patients, with more overall tyrosine kinase activity in inflamed mucosa in UC, and serine/threonine kinase activity in inflamed mucosa in CD as compared with non-inflamed mucosa (Figure 1). The kinase activity profile of non-inflamed mucosa of CD and UC patients was similarly different from mucosa of healthy control participants (Figure 2). The cytokine and chemokine profile of inflamed biopsies differed from non-inflamed IBD biopsies and healthy control biopsies, with higher levels of S100A8, TNFα, IL-6, oncostatin M (OSM) and triggering receptor expressed on myeloid cells-1 (TREM-1), amongst others (Figure 3). Conclusion In IBD, inflammation in the mucosa can be characterised both by explant-culture and kinase activity assessment. The difference in kinase activity between non-inflamed IBD mucosa and healthy control mucosa suggests the presence of sub-clinical alterations in cell signalling. The observed differences in the kinase, cytokine and chemokine profiles underscore the importance of this approach in the elucidation of the pathophysiology in IBD.

scholarly journals Prevalence of Joint Hypermobility and Patterns of Articular Manifestations in Patients with Inflammatory Bowel Disease

2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
P. Vounotrypidis ◽  
E. Efremidou ◽  
P. Zezos ◽  
M. Pitiakoudis ◽  
E. Maltezos ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Study Groups ◽  
Joint Hypermobility ◽  
Fisher Exact Test ◽  
Hypermobility Syndrome ◽  
Exact Test ◽  
Significant Difference ◽  
Healthy Control ◽  
Inflammatory Bowel

Objective. The objective is the investigation of Joint Hypermobility (JH) and the Hypermobility Syndrome (HMS) in patients with inflammatory bowel disease (IBD).Methods. We examined 83 patients with IBD and 67 healthy individuals for the presence of JH. Patients were excluded if they were under 18 or over 50 years of age and if they had other conditions which affect joint mobility. Thex2and the Fisher exact test were used appropriately between study groups. Odds ratios (ORs) for the risk of JH and HMS in IBD groups were calculated.Results. A total of 150 individuals (83 IBD patients and 67 healthy controls) participated in the study. 69 IBD patients, 41 with Crohn's Disease (CD) and 28 with ulcerative colitis (UC), were finally eligible. JH was detected in 29 CD patients (70.7%), in 10 UC patients (35.7%), and in 17 healthy control subjects (25.4%). Significant difference was detected on JH in CD patients as compared to UC patients (P=.0063) and controls (P<.0001). The estimated OR for JH was 7.108 (95% CI: 2.98–16.95) in CD and 1.634 (95% CI: 0.63–4.22) in UC patients. HMS was detected in 5 (12.2%) CD and in 1 (3.57%) UC patients. The OR for HMS in CD was 3.75 (95% CI: 0.41–34.007), while 7 (17.1%) CD patients had overlapping symptoms for both HMS and early spondylarthropathy.Conclusions. JH and the HMS are common in CD patients, thus articular manifestations should be carefully interpreted. This implies an involvement of collagen varieties in the pathogenesis of IBD.

Eating disorder or disordered eating: undiagnosed inflammatory bowel disease mimicking eating disorder

2018 ◽  
Vol 104 (10) ◽  
pp. 1004-1006
Author(s):  
Rachel Elizabeth Harris ◽  
Rachel Tayler ◽  
Richard K Russell
Keyword(s):  
Inflammatory Bowel Disease ◽  
Eating Disorder ◽  
Disordered Eating ◽  
Bowel Disease ◽  
Eating Habits ◽  
Delayed Diagnosis ◽  
Important Differential Diagnosis ◽  
Gi Symptoms ◽  
Incorrect Diagnosis ◽  
Inflammatory Bowel

We describe the case of a patient with ongoing weight loss, low mood and previously undisclosed gastrointestinal (GI) symptoms initially diagnosed with an eating disorder and subsequently diagnosed with ulcerative colitis over a year following initial presentation. This patient exhibited disordered eating secondary to the worsening symptoms of undiagnosed inflammatory bowel disease (IBD) and had altered her eating habits to reduce the diarrhoea and rectal bleeding she was experiencing, contributing to significant weight loss.The implications of a delayed diagnosis of IBD or incorrect diagnosis of eating disorder are severe both physically and psychologically. We discuss factors in the assessment of patients which may raise suspicion of organic GI disease such as IBD—an important differential diagnosis in those with non-specific GI symptoms and suspected eating disorder—and highlight baseline investigations which should be performed to ensure a diagnosis of IBD is not missed in these patients.

scholarly journals Eating habits in patients with inflammatory bowel disease

2021 ◽  
Vol 11 (8) ◽  
pp. 255-260
Author(s):  
Aleksandra Iwona Zimna ◽  
Hubert Wróblewski
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Eating Habits ◽  
Meat Products ◽  
White Bread ◽  
Blue Cheese ◽  
Inflammatory Bowel

Wstęp : Wrzodziejące zapalenie jelita grubego i choroba Leśniowskiego-Crohna są najczęstszymi chorobami zapalnymi jelit. Farmakoterapia odgrywa dużą rolę w leczeniu zarówno zaostrzeń, jak i remisji, jednak ważna jest również dieta, którą należy dobierać indywidualnie do potrzeb pacjenta, zwłaszcza biorąc pod uwagę potrzeby pacjenta. reakcja na pokarm i objawy, których obecnie doświadczasz. Celem wprowadzenia diety jest m.in. ułatwienie regeneracji jelit, przyspieszenie i wydłużenie okresu remisji choroby oraz zapobieganie niedożywieniu u pacjentów.Cel: Celem pracy jest analiza nawyków żywieniowych i diety pacjentów z IBD w okresie remisji.Materials and methods: The results were obtained on the basis of a questionnaire survey.Results: 95 people took part in the survey, 56.4% of them suffer from UC and 43.6% from CDI, 48.5% of respondents admit that they smoke more than 10 cigarettes a day. As many as 43.6% do not do any sports More than half of respondents eat white bread and exclude blue cheese from the diet. 24.5% of respondents are mostly meat products and 13.8% - vegetables. Only 27% of respondents use probiotics, only 40% consume pickled products regularly. Almost 6% do not eat fish and 35 people do it sporadically, unlike poultry, which is eaten several times a week by less than half of the respondents, 27 of the respondents excluded smoked meats from their diets. Only 25% of the respondents do not consume NSAIDs, while for 6% their consumption is everyday life.Wnioski: Z przeprowadzonych badań wynika, że istnieje ciągła potrzeba edukowania pacjentów w zakresie zdrowego stylu życia, w tym promowania aktywności fizycznej oraz przestrzegania szkodliwego wpływu palenia na ich zdrowie, życie i przebieg chorób poprzez podkreślanie CDD, ponieważ palenie tytoniu pogłębia tę chorobę , podobnie jak zażywanie NLPZ. Analizując uzyskane wyniki należy zwrócić uwagę na małe zainteresowanie spożywaniem probiotyków, które mają pozytywny wpływ na mikroflorę jelitową oraz podkreślić korzyści płynące ze spożywania produktów marynowanych. Wydaje się, że dobór produktów spożywczych i stosowanej przez respondentów diety jest wyrazem indywidualnych potrzeb, subiektywnych przekonań i preferencji

scholarly journals Faecal calprotectin: A reliable diagnostic and prognostic biomarker in inflammatory bowel disease

2017 ◽  
Vol 8 (1) ◽  
pp. 12-15
Author(s):  
Ripon Barua ◽  
Najmun Nahar ◽  
Jogendra Nath Sarker ◽  
Sultana Razia ◽  
Abu Naser Ibne Sattar ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Medical Treatment ◽  
Disease Control ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Cross Sectional Study ◽  
Faecal Calprotectin ◽  
Cross Sectional ◽  
Healthy Control ◽  
Inflammatory Bowel

Faecal calprotectin (FC) is supposed to be a reliable biomarker that quantifies intestinal inflammation in inflammatory bowel disease (IBD). This cross sectional study was aimed to determine the role of FC level in screening of suspected IBD patients and monitoring treatment response. This study was conducted by measurement of FC using a commercially available ELISA kit among 50 patients with chronic diarrhea who underwent colonoscopic evaluation (25 IBD cases, 10 other organic bowel diseases and 15 disease control) and 12 healthy control. IBD patients were followed up after one month of medical treatment. FC level showed significantly higher value (p<0.001) among IBD patients (496.7±127.15?g/g) than those in disease control (82.17±75.64?g/g) and healthy control (27±18.2?g/g). Measurement of FC in diagnosing IBD revealed the sensitivity 100%, specificity 66%, PPV 83% and NPV 100%. The FC level decreased significantly (p<0.001) after one month of medical treatment of IBD patients (90±43?g/g) from pre treatment value (607.56±94?g/g). FC can be used as a reliable biomarker in screening of suspected IBD patients and to monitor treatment response.Bangladesh J Med Microbiol 2014; 08 (01): 12-15

scholarly journals Simultaneous Quantitation of Lipid Biomarkers for Inflammatory Bowel Disease Using LC–MS/MS

Metabolites ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 106
Author(s):  
Yashpal S. Chhonker ◽  
Shrey Kanvinde ◽  
Rizwan Ahmad ◽  
Amar B. Singh ◽  
David Oupický ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dynamic Range ◽  
Response To Therapy ◽  
Limit Of Quantification ◽  
Highly Sensitive ◽  
The Us ◽  
Healthy Control ◽  
Inflammatory Bowel ◽  
And Oxidative Stress

Eicosanoids are key mediators and regulators of inflammation and oxidative stress that are often used as biomarkers for severity and therapeutic responses in various diseases. We here report a highly sensitive LC-MS/MS method for the simultaneous quantification of at least 66 key eicosanoids in a widely used murine model of colitis. Chromatographic separation was achieved with Shim-Pack XR-ODSIII, 150 × 2.00 mm, 2.2 µm. The mobile phase was operated in gradient conditions and consisted of acetonitrile and 0.1% acetic acid in water with a total flow of 0.37 mL/min. This method is sensitive, with a limit of quantification ranging from 0.01 to 1 ng/mL for the various analytes, has a large dynamic range (200 ng/mL), and a total run time of 25 min. The inter- and intraday accuracy (85–115%), precision (≥85%), and recovery (40–90%) met the acceptance criteria per the US Food and Drug Administration guidelines. This method was successfully applied to evaluate eicosanoid metabolites in mice subjected to colitis versus untreated, healthy control mice. In summary, we developed a highly sensitive and fast LC−MS/MS method that can be used to identify biomarkers for inflammation and potentially help in prognosis of the disease in inflammatory bowel disease (IBD) patients, including the response to therapy.

scholarly journals An Analysis and Survey on Interleukin-10 Receptor Mutation in Inflammatory Bowel Disease in Iranian IBD Cohort

2019 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Early Onset ◽  
Pcr Amplification ◽  
Interleukin 10 ◽  
Genes Encoding ◽  
Healthy Control ◽  
Inflammatory Bowel ◽  
Total Dna

Background: Early-onset inflammatory bowel disease (IBD) is classified to Crohn’s disease, ulcerative colitis and unclassified disorders which have chronic, relapsing course and can result in substantial long-term morbidity. IBD is a multifactorial disorder with genetic susceptibility, immunological predisposition and environmental triggers. Objective: To generally determine prevalence of IL10R mutation in IBD patients in Iran-Isfahan, we performed sequencing of all exons in IL10RA and IL10RB in cohort of IBD patients and healthy control. Material and Method: Total DNA content of 76 patients and 50 healthy controls were extracted from whole blood and PCR amplification and sequencing was done. Result: Overall identified IL-10RA mutations were P.(I224V), P.(A153V), P.(A153A), P.(S159G), P.(R263Q), P.(R284C), P.(R351Q), P.(Q376Q), P.(T416I), P.(A493V), P.(A511A) and P.(S563S). In IL10RB gene the only detected mutation was P. (K47E). Of them, P.(A153V), P.(A153A), P.(R284C), P.(T416I), P.(A493V), P.(A511A), P.(S563S) were Not reported variant in IBD variants. Conclusion: Our results also confirmed that early-onset IBD could be attributed to a synergistic effect of several variant alleles of the genes encoding IL10 receptors. These variants, alone, could only give rise to a sub-clinical manifestation of the IBD.

Sign in / Sign up

Export Citation Format

Share Document